BidaskClub downgraded shares of Eagle Pharmaceuticals (NASDAQ:EGRX) from a hold rating to a sell rating in a report released on Friday morning.
Several other brokerages have also recently weighed in on EGRX. Piper Jaffray Companies cut shares of Eagle Pharmaceuticals from an overweight rating to a neutral rating and dropped their price objective for the stock from $82.00 to $54.00 in a research note on Wednesday, October 31st. Cantor Fitzgerald set a $80.00 price objective on shares of Eagle Pharmaceuticals and gave the stock a buy rating in a research note on Wednesday, October 3rd. TheStreet lowered shares of Eagle Pharmaceuticals from a b- rating to a c+ rating in a report on Tuesday, September 25th. Mizuho decreased their target price on shares of Eagle Pharmaceuticals to $52.00 and set a neutral rating on the stock in a report on Wednesday, November 7th. Finally, Royal Bank of Canada set a $64.00 target price on shares of Eagle Pharmaceuticals and gave the company a buy rating in a report on Friday, November 2nd. Two analysts have rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. The stock has a consensus rating of Hold and a consensus price target of $77.17.
Shares of Eagle Pharmaceuticals stock opened at $43.90 on Friday. Eagle Pharmaceuticals has a twelve month low of $43.88 and a twelve month high of $85.66. The company has a quick ratio of 5.38, a current ratio of 5.59 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $702.86 million, a price-to-earnings ratio of 13.03 and a beta of 1.71.
Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its quarterly earnings data on Thursday, November 1st. The specialty pharmaceutical company reported $1.18 earnings per share for the quarter, topping the consensus estimate of $0.91 by $0.27. Eagle Pharmaceuticals had a net margin of 13.92% and a return on equity of 17.62%. The business had revenue of $51.34 million during the quarter, compared to analysts’ expectations of $52.70 million. During the same quarter in the previous year, the company earned $1.22 EPS. The business’s revenue was down 18.5% on a year-over-year basis. As a group, equities research analysts expect that Eagle Pharmaceuticals will post 2.03 EPS for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the business. Itau Unibanco Holding S.A. bought a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter valued at approximately $108,000. Macquarie Group Ltd. grew its holdings in shares of Eagle Pharmaceuticals by 400.0% during the 2nd quarter. Macquarie Group Ltd. now owns 1,500 shares of the specialty pharmaceutical company’s stock valued at $113,000 after purchasing an additional 1,200 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of Eagle Pharmaceuticals during the 3rd quarter valued at approximately $115,000. Piedmont Investment Advisors LLC bought a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter valued at approximately $150,000. Finally, Robeco Institutional Asset Management B.V. bought a new stake in shares of Eagle Pharmaceuticals during the 3rd quarter valued at approximately $156,000.
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).
Further Reading: What are Institutional Investors?
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.